<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680260</url>
  </required_header>
  <id_info>
    <org_study_id>KFE2022</org_study_id>
    <nct_id>NCT04680260</nct_id>
  </id_info>
  <brief_title>OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer</brief_title>
  <acronym>OPTIMISE</acronym>
  <official_title>OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer - a ctDNA Guided Phase II Randomized Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karen-Lise Garm Spindler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant&#xD;
      treatment in patients with advanced colorectal cancer (CRC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label 1:1 randomized phase II exploratory study investigating use of ctDNA-guided&#xD;
      adjuvant chemotherapy compared to standard of care (SOC) after local treatment for metastatic&#xD;
      colorectal cancer.&#xD;
&#xD;
      Patients are randomized 1:1 between SOC and ctDNA guided treatment and follow-up.&#xD;
&#xD;
      Escalation therapy comprises standard regimen of Fluorouracil (5-FU), Irinotecan and&#xD;
      oxaliplatin (FOLFOXIRI), de-escalation therapy of monotherapy capecitabine or observation&#xD;
      only. SOC is per institutional practice, based on national guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An open label 1:1 randomized phase II exploratory study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Free Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of patients free from recurrent colorectal cancer at 2 years post local treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Rate of grade 3-4 toxicity according to CTCAE version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular biological response to therapy</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Rate of patients with lack of detectable tumor DNA in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular biological Disease Free Survival</measure>
    <time_frame>1 year from inclusion</time_frame>
    <description>Rate of patients with no detectable ctDNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to molecular biological recurrence</measure>
    <time_frame>5 years last patient</time_frame>
    <description>Time to molecular biological recurrence is calculated from first time of no detectable DNA until detectable DNA in a samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiological recurrence</measure>
    <time_frame>5 years last patient</time_frame>
    <description>Time to radiological recurrence is calculated from inclusion until radiological evidence of disease recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and distant relapse</measure>
    <time_frame>5 years last patient</time_frame>
    <description>Rate of patients with local and distant relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years last patient</time_frame>
    <description>Time from inclusion to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and questionnaires for patient preference</measure>
    <time_frame>5 years last patient</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaire C30 (core) + CR29 (colorectal) The EORTC QLQ-CR29 is a tumor-specific health related QoL questionnaire module for CRC patients, which is designed to complement the EORTC QLQ-C30 questionnaire. Patients are asked to indicate their symptoms during the past week(s). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>5 years last patient</time_frame>
    <description>Economic evaluation of ctDNA guided chemotherapy after curative treatment of metastatic colorectal cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>A: Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: ctDNA guided therapy approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post ablation ctDNA results will be used for treatment decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.</description>
    <arm_group_label>A: Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Circulating tumor DNA guided treatment approach</intervention_name>
    <description>Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.</description>
    <arm_group_label>B: ctDNA guided therapy approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radical intended treatment for metastatic spread from CRC, by resection,&#xD;
             radiofrequency ablation, stereotactic body radiation therapy (or other experimental&#xD;
             local treatment options)&#xD;
&#xD;
          -  No evidence of further disease based on pre-treatment work-up according to SOC&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-2&#xD;
&#xD;
          -  Clinically eligible for adjuvant triple CT at investigators decision.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function allowing systemic chemotherapy&#xD;
             (Absolute neutrophil count ≥1.5x109/l and thrombocytes ≥ 100x109/l. Bilirubin ≤ 1.5 x&#xD;
             upper normal value and alanine aminotransferase ≤ 3 x upper normal value, and&#xD;
             calculated or measured renal glomerular filtration rate at least 30 mL/min)&#xD;
&#xD;
          -  Anticonception for fertile women and for male patients with a fertile partner.&#xD;
             Intrauterine device, vasectomy of a female subject's male partner or hormonal&#xD;
             contraceptive are acceptable&#xD;
&#xD;
          -  Written and verbally informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiological evidence of distant metastasis, by CT- chest, abdomen, and pelvis&#xD;
&#xD;
          -  Incapacity, frailty, disability and comorbidity to a degree that according to the&#xD;
             investigator is not compatible with triple combination chemotherapy&#xD;
&#xD;
          -  Neuropathy National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI-CTCAE) grade &gt; 1&#xD;
&#xD;
          -  Other malignant tumor within 5 years except non-melanoma skin cancer or carcinoma in&#xD;
             situ cervicis uteri&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or breast feeding women&#xD;
&#xD;
          -  Intolerance or allergy to 5FU, leucovorin, oxaliplatin, irinotecan or capecitabine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen-Lise G Spindler, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen-Lise G Spindler, Professor</last_name>
    <phone>+4591167244</phone>
    <email>k.g.spindler@rm.dk</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Karen-Lise Garm Spindler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Circulating tumor DNA</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

